Literature DB >> 33089343

Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.

Wen-Long Yu1, Guanzhen Yu2, Hui Dong3, Ke Chen4, Jun Xie5, Hua Yu3, Yuan Ji4, Guang-Shun Yang6, Ai-Jun Li7, Wen-Ming Cong8, Guang-Zhi Jin9.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common tumor in primary liver cancer, but the prognostic factors associated with long-term outcomes after surgical resection remain poorly defined. This study aimed to develop a novel prognostic classifier for patients with ICC after surgery.
METHODS: Using a proteomics approach, we screened tumor markers that up-regulated in ICC tissues, and narrowed down by bioinformatics analysis, western blot and immunohistochemistry. Prognostic markers were identified using Cox regression analyses in primary training cohort and the predictive models for time to recurrence (TTR) were established. The predictive accuracy of predictive model was validated in external validation cohort and prospective validation cohort. MTT assay, clonal formation assay and trans-well assays were used to verify the effect on the proliferation and migration in ICC cell line.
RESULTS: Triosephosphate isomerise (TPI1) was significantly up-regulated in ICC tissues and Kaplan-Meier analysis reveals that higher TPI1 expression was strongly correlated with higher recurrence rate of ICC patients. In the primary training cohort, mean TTR was significantly longer (p < 0.0001) than in the low-risk group (26.9 months for TTR, 95% CI 22.4-31.5) than in the high-risk group (14.5 months for TTR, 95% CI 10.6-18.4). Similar results were observed in two validation cohorts. In addition, a nomogram to predict recurrence was developed. Moreover, Knockdown of TPI1 by shRNA inhibited ICC cell growth, colony information, migration, invasion in vitro.
CONCLUSIONS: Current prognostic models were accurate in predicting recurrence for ICC patients after surgical resection.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; Proteomics; Recurrence; Triosephosphate isomerise

Year:  2020        PMID: 33089343     DOI: 10.1007/s00535-020-01729-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  7 in total

1.  Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.

Authors:  Zhengnan Huang; Yilin Yan; Tengjiao Wang; Zeyi Wang; Jinming Cai; Xiangqian Cao; Chenkai Yang; Fang Zhang; Gang Wu; Bing Shen
Journal:  J Transl Med       Date:  2022-07-14       Impact factor: 8.440

2.  TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5.

Authors:  Xiaoying Jin; Dandan Wang; Mengxia Lei; Yan Guo; Yuqing Cui; Fengzhi Chen; Weiling Sun; Xuesong Chen
Journal:  J Transl Med       Date:  2022-05-04       Impact factor: 8.440

3.  Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma.

Authors:  Wenhu Liu; Qiang Wang; Jinxia Chang; Anup Bhetuwal; Nisha Bhattarai; Fan Zhang; Jiancai Tang
Journal:  Clin Proteomics       Date:  2022-05-24       Impact factor: 5.000

4.  Systemic Analyses of the Expression of TPI1 and Its Associations with Tumor Microenvironment in Lung Adenocarcinoma and Squamous Cell Carcinoma.

Authors:  Xiaodong Yang; Cong Ye; Hui Zheng; Chenyang Dai; Yuming Zhu
Journal:  Dis Markers       Date:  2022-01-25       Impact factor: 3.434

5.  Robust Validation and Comprehensive Analysis of a Novel Signature Derived from Crucial Metabolic Pathways of Pancreatic Ductal Adenocarcinoma.

Authors:  Wenchao Gu; Shaocong Mo; Yulin Wang; Reika Kawabata-Iwakawa; Wei Zhang; Zongcheng Yang; Chenyu Sun; Yoshito Tsushima; Huaxiang Xu; Takahito Nakajima
Journal:  Cancers (Basel)       Date:  2022-04-04       Impact factor: 6.639

6.  A Nomogram Model to Predict Early Recurrence of Patients With Intrahepatic Cholangiocarcinoma for Adjuvant Chemotherapy Guidance: A Multi-Institutional Analysis.

Authors:  Qi Li; Jian Zhang; Chen Chen; Tianqiang Song; Yinghe Qiu; Xianhai Mao; Hong Wu; Yu He; Zhangjun Cheng; Wenlong Zhai; Jingdong Li; Dong Zhang; Zhimin Geng; Zhaohui Tang
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 7.  Quantitative proteomics characterization of cancer biomarkers and treatment.

Authors:  Xiao-Li Yang; Yi Shi; Dan-Dan Zhang; Rui Xin; Jing Deng; Ting-Miao Wu; Hui-Min Wang; Pei-Yao Wang; Ji-Bin Liu; Wen Li; Yu-Shui Ma; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-04-20       Impact factor: 7.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.